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Summary 
Objectives: Since previous reviews of epidemiologic studies of premature mortality 
among people with epilepsy were completed several years ago, a large body of new 
evidence about this subject has been published.  We aim to update prior reviews of 
mortality in epilepsy and to re-evaluate and quantify the risks, potential risk factors, and 
causes of these deaths.  
Methods: We systematically searched the MEDLINE and EMBASE databases to 
identify published reports describing mortality risks in cohorts and populations of people 
with epilepsy.  We reviewed relevant reports and applied criteria to identify those 
studies likely to accurately quantify these risks in representative populations.  From 
these we extracted and summarized the reported data. 
Results:  All population-based studies reported an increased risk of premature mortality 
among people with epilepsy compared to general populations.  Standard mortality ratios 
are especially high among people with epilepsy aged less than 50 years, among those 
whose epilepsy is categorized as structural/metabolic, those whose seizures do not fully 
remit under treatment, and those with convulsive seizures.  Among deaths directly 
attributable to epilepsy or seizures, important immediate causes include sudden 
unexpected death in epilepsy, status epilepticus, unintentional injuries, and suicide. 
Significance:  Epilepsy-associated premature mortality imposes a significant public 
health burden, and many of the specific causes of death are potentially preventable.  
These require increased attention from health care providers, researchers, and public 
health professionals. 
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Key Points: 
 Epilepsy-associated mortality imposes a significant burden on the public health of 
high-income countries 
 Important causes of death among people with epilepsy include injuries, status 
epilepticus, and SUDEP, which may be preventable with access to high quality 
specialty health care.  
 Limitations of existing studies of epilepsy-associated mortality indicate a need for 
additional epidemiologic studies and the development of methods and systems 
for long-term surveillance of mortality in people with epilepsy. 
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Introduction 
Previous reviews focused on epidemiologic studies of all-cause mortality among people 
with epilepsy1-5 have found that the condition carries an overall increased risk of 
premature death, have identified risk factors and characteristics of epilepsy associated 
with premature mortality, and have provided information on the proportions of deaths 
attributable to specific causes among people with epilepsy.  These reviews also reveal 
considerable variability in these estimates. 
The variability in such estimates can be mainly attributed to actual differences in risk of 
premature death among the various populations ascertained and to differences in study 
methodology.  Valid methods for determining death in people with epilepsy depend on 
accurate diagnoses of epilepsy, as well as complete and accurate determinations of the 
numbers of deaths and the specific causes thereof among the populations studied.  If 
studies are population-based, full ascertainment of epilepsy cases in those populations 
is necessary.  Most reviews to date have not systematically characterized the quality of 
methods among the published reviews. 
The reviews cited above were completed several years ago and since then a large body 
of new evidence about mortality in epilepsy has been published.  Accordingly, there is a 
need to assess systematically new and older evidence, specifically for high-income 
world regions as well as low- and middle-income world regions.  This evidence is 
essential for assigning priorities for prevention strategies. 
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This review aims to update past assessments of the epidemiology of premature 
mortality among people with epilepsy. We also aim to re-evaluate and quantify risks, 
risk factors, and causes of these deaths, with special attention to deaths consequent to 
the underlying etiologies of epilepsy and deaths consequent to epilepsy itself or its 
treatment.  Where this review identifies preventable causes, this knowledge will support 
the development of strategies and programs to reduce the burden of mortality in 
epilepsy.  This review focuses on mortality in higher-income countries (HIC); a 
companion review focuses on mortality in lower- and middle-income countries. 
 
Methods 
In this systematic review we used standards provided in “Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement."6 
Definitions.  Various measures of risk are employed among published studies of 
mortality in epilepsy, which sometimes impose difficulties comparing findings across 
studies.  In this review we consider both absolute and comparative risk measures. 
Incidence rates of death or specific causes of death are absolute measures that may be 
reported in population-based studies.  We describe incidence rates as annual numbers 
of deaths per 1000 persons with epilepsy.   
Many studies also employ comparative risk measures, intended to convey the relative 
magnitude of risk among population groups.  Within subpopulations of a study, 
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incidence rates may be compared using a rate ratio (RR), which may be crude or 
adjusted for potentially confounding variables such as age and sex.  Incidence rates 
between studies are best compared when they are directly standardized by age (or age 
and sex) to the same reference population.  A similar comparative incidence measure is 
the hazard ratio (HR), which takes more detailed account of individual subject survival 
time, using regression modelling.7  
The standardized mortality ratio (SMR) is the commonest most common comparative 
risk measure encountered in this review.  This is defined as the ratio of the observed 
numbers of deaths in the study population (with epilepsy) to the expected number of 
deaths estimated by standardization to the reference population (without epilepsy).  The 
reference population is usually the base population of the study.  Thus, SMRs are 
standardized only within each study, and because distributions of subject characteristics 
such as age, sex, and other extraneous mortality risk factors may vary considerably 
among different studies, comparisons of SMRs between studies must be made with 
caution because of the likelihood of residual confounding by such factors.7   
Other comparative risk measures occasionally encountered in this review are odds 
ratios (ORs) employed in case-control studies and multivariate analyses. 
Search strategy.  We used the Ovid® MEDLINE (Ovid) and Embase® database search 
engines to find relevant references.  Search terms in MEDLINE included any of the 
following Medical Subject Headings, with subheadings indicated by brackets and term 
combinations indicated by ‘AND’ used as a Boolean operator: 
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 Epilepsy [epidemiology] AND Epilepsy [mortality] 
 Epilepsy AND Mortality 
 Epilepsy AND ‘Sudden death’ [epidemiology] 
 Epilepsy AND Death [etiology]  
 Epilepsy AND ‘Wounds and Injuries’ (and subheadings) [mortality]  
We did not restrict the search by language, but limited our search to human studies and 
excluded case reports.  Similarly, we also used the EMBASE search engine to retrieve 
references indexed under both epilepsy and mortality, when both subjects were 
indicated as the focus of the report.  We reviewed the retrieved titles and abstracts to 
identify original reports that provided new data including measures of mortality for 
people with epilepsy, e.g., mortality incidence rates, SMRs, proportionate mortality 
ratios, or other comparative risk ratios.  We included studies that were population- or 
community-based, as well as clinical cohort or case-control studies. We obtained and 
reviewed full-length reports for all references whose titles or abstracts suggested the 
articles might meet these criteria.  The full search strategy using both database search 
engines—and the criteria for screening titles and abstracts—are described in 
Supporting Table 1a.   
Evaluation of strength of evidence.  These full reports were each examined by a pair of 
reviewers, who assessed their relevancy, strength of evidence, and who abstracted 
relevant data.  Differences in assessments of relevance or quality of evidence were 
resolved by consensus of the reviewer pairs after reconsideration.  The criteria by which 
we assessed the quality of evidence included: 
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 sensitivity of epilepsy case ascertainment,  
 sensitivity of mortality case ascertainment,   
 accuracy of diagnoses of epilepsy,  
 accuracy of diagnoses of cause of death, 
 representativeness of the study population. 
We assigned each report to categories designated as Class 1 through Class 4, 
representing highest strongest through lowest weakest strength of evidence, 
respectively.  From the bibliographic citations of Class 1 – 3 articles, we also sought 
relevant eligible reports not previously identified in the original search and screening 
efforts. A more complete description of these quality assessment criteria and 
corresponding classes of evidence is included in Supporting Table 1b available online. 
 
Findings 
Search results.  Searches of MEDLINE and EMBASEmbase conducted in November 
2011 and updated in February 2014 and June 2016 in sum yielded 495 607 article 
citations.  Results of the search and screening are detailed in Figure 1. A total of 54 46 
reports met all inclusion criteria with strength of evidence rated ≥ ‘Class 3’, representing 
high -income countries.  Although three reports represented different findings over time 
from a single cohort from the United Kingdom8-10 and two reports from a single cohort in 
Austria11; 12, their findings were included when they represented separate 
measurements. 
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Overall risk of mortality.  Seventeen studies provided SMRs estimating the risk of 
premature death for people with epilepsy compared to reference populations as shown 
in Table 1.  Nine of these were population-based, including all ages or all adult ages,8; 
10; 13-19 two of which represented the same cohort.8; 10  All of these nine showed 
significant elevations of their SMRs ranging from 1.6 to 3.0.  Among 6 of these 
population-based studies representing incidence cohorts including all ages, the 
weighted median SMR was 2.3.  Among three population-based studies of children20-22 
there were considerably higher SMRs ranging from 6.4 to 7.5. 
Three Four clinic- or hospital-based cohort studies of epilepsy patients, including all 
ages or all adults, yielded SMRs ranging from 1.4 to 3.6.11; 12; 23; 24  Two clinic-based 
cohort studies of children yielded higher SMRs of 7.0 and 7.5.25; 26 
Mortality risk by sex.  Supporting Table 2 summarizes the findings of seven studies 
comparing risks of death from all causes between females and males.12-14; 16; 17; 24; 27  
With one exception,27 studies showed elevated SMRs for both females and males. 
Mortality risk by age.  Nine studies reported age-specific SMRs for people with epilepsy. 
summarized in Supporting Table 3. 8; 14; 16; 20; 22; 24-26; 28  The highest SMR (22.3) 
represented persons with onset of epilepsy in the first year of life.  Considering only 
class 1 and 2 studies that report SMRs by age-at-death interval,8; 14; 20; 22 consistently 
higher SMRs were reported in all age groups younger than 45 years (range 6.4 to 8.5), 
while comparatively lower SMR elevations were reported in age groups older than 64 
years (range 1.4 to 2.6). The distribution of SMRs by age at death is illustrated in Figure 
2. 
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Risk by interval from time of diagnosis.  Class 1 and 2 incident cohort studies of three 
populations of people diagnosed with epilepsy or unprovoked seizures reported higher 
SMRs during the earliest measured time intervals following diagnosis, diminishing in 
subsequent intervals (Figure 3).14; 15; 18 This effect may, however, in part be attributable 
to confounding by age, considering that epilepsy incidence is higher in children for 
whom mortality rates of the base population are lower than among older populations.  
We also found that among Class 2 studies that measured mortality separately for 
remote symptomatic epilepsy vs. idiopathic or cryptogenic epilepsy, the early elevation 
of mortality risk after diagnosis was mainly observed in the symptomatic group.18; 29   
Risk by seizure type.  Three population-based cohort studies of incident epilepsy16; 19 or 
incident epilepsy and first unprovoked seizure13 provided estimates of risk according to 
the type of seizures experienced by their subjects as listed in Supporting Table 4.  For 
those with generalized tonic-clonic seizures, a Swedish study 16 reported a significantly 
elevated SMR of 3.9 for males; the corresponding SMR was also elevated for females, 
but not at a statistically significant level.  For subjects with partial seizures with 
secondary generalization, an Estonian study19 reported an SMR of 2.7, compared to an 
SMR of 1.5 for subjects with simple partial seizures.  For those with focal seizures not 
further characterized, two studies13; 16 reported significantly elevated SMRs of 2.1 and 
1.8.  One of these reported only a slight, statistically insignificant elevation of SMR of 
1.3 among those in their cohort with generalized seizures that were not further 
classified.13 
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Risk by etiology of epilepsy.  Nine studies8; 10; 12-15; 18; 19; 23 summarized in Supporting 
Table 5 reported SMRs according to these broad categories of cause of epilepsy: 
cryptogenic, idiopathic, or symptomatic.*  The highest risks are measured among people 
with epilepsy with symptomatic seizures; among class 1 and 2 studies, 8; 10; 13-15; 18; 19 
SMRs were all significantly elevated, with a range of 2.2 to 4.3.  Modest SMR elevations 
were observed in most class 1 and 2 studies addressing cryptogenic or idiopathic 
causes, 8; 10; 13-15; 18; 19 with estimates ranging from 0.9 to 2.1, only some of which were 
statistically significant. 
Risk by comorbid brain disorders among people with epilepsy. Table 2 describes data 
from eleven thirteen studies that assessed the risk of death among subjects with 
comorbid neurologic conditions considered to bepotentially causal to their epilepsy.8-11; 
14; 15; 20; 21; 25; 26; 30-32  Very high measurements of risk, with SMRs ranging from 11 to 50, 
were found for subjects with central nervous system conditions described in various 
general terms among the studies, summarized here as static or progressive 
encephalopathies, including major congenital and acquired central nervous system 
deficits.  Similarly high measurements of risk were also found for the more specific 
category comprising intellectual disability (mental retardation) and cerebral palsy, and 
for the category of brain tumor.  Lesser, but still substantial risk elevations were found in 
people with epilepsy attributed to cerebrovascular disease or to diseases characterized 
by dementia. 
                                              
* These categories are described in terminologies of older International League Against Epilepsy (ILAE) 
classifications that were in effect at the times these studies were completed.  These older descriptors of 
etiology correspond approximately to newer terms recommended in 2010 by the ILAE Commission on 
Classification and Terminology as follows: ‘cryptogenic’ – unknown, ‘idiopathic’ – genetic or presumed 
genetic, and ‘symptomatic’ – structural-metabolic.    
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Risk in people still having seizures under treatment.  Seven cohort studies summarized 
in Supporting Table 6 estimated risk of death among various epilepsy populations 
known or likely to have continued seizures despite treatment.12; 33-38  All measures 
indicated elevated levels of risk.  Rate ratios (RRs) comparing risk to people with 
epilepsy who are seizure-free were especially high, with estimates of 9.3 and 13.4.34; 35 
Risk of sudden unexpected death in epilepsy (SUDEP).  The risk of SUDEP, which 
excludes deaths attributable to structural or external causes determined from death 
investigation or prior clinical diagnosis, is estimated in two groups of studies: general 
community-based populations and clinical cohorts.  As summarized in Supporting Table 
7, SUDEP occurrence in general populations of people with epilepsy was addressed by 
8 community-based studies,23; 39-44  among which reported rates varied substantially.  
Among studies including all age groups,23; 39; 41; 43; 44 estimates ranged from 0.33 to 1.35 
cases of SUDEP annually per 1000 people with epilepsy.  Two community-based 
studies limited to children40; 45  estimated lower annual rates of 0.20 and 0.43 per 1000.  
Nine clinic-based studies, mainly representing people with treatment-resistant epilepsy, 
yielded higher estimates of SUDEP occurrence, ranging from 1.2 to 6.3 cases of 
SUDEP annually per 1000 individuals.23; 33; 37; 46-51    
Risk of death from status epilepticus among people with epilepsy.  We found one class 
115 and  three class 3 studies,37; 39; 50 all from the United Kingdom, describing the 
occurrence of fatal status epilepticus (Supporting Table 8).  Two population-based 
studies, one encompassing all ages15 and the other encompassing children only,39, 
yielded estimated annual rates of 0.1 and 0.2 cases per 1000 persons with epilepsy, 
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respectively.  A study of children with epilepsy enrolled in a residential school for 
learning disabilities yielded an annual rate of 1.0 cases per 1000 children.50 Another 
study of people with epilepsy treated in a tertiary referral center yielded an annual rate 
of 0.4 cases per 1000 attendees.37  Across these four studies, 1.9% of all deaths were 
attributed to status epilepticus. 
Risk of fatal injury.  As summarized in Table 3, four six studies described the risk of 
death from injuries among people with epilepsy.11; 23; 24; 27; 52; 53  In two four studies there 
were substantial signficant elevations in the overall risk from all causes of injuries, one 
showing an adjusted odds ratio (aOR) of  3.6,52 and an SMR of others showing SMRs 
ranging from 2.0 to 5.6.11; 24; 27  Especially high risk estimates were found for drowning 
(or submersion or suffocation injuries), with SMRs ranging from 2.10 to 13.8, and an 
aOR of 7.7.11; 23; 24; 27; 52; 53  The risk of death from falls was also high, with an SMR of 
4.6 and an aOR of 8.5.  The elevated risk of suicide was also noteworthy, with SMRs of 
2.6 to 5.011; 23; 24; 27 and an aOR of 3.7.52 
Risk of death by categories of disease.  As summarized in Table 4, five seven studies 
described risks of death attributable to broad disease categories.9; 11; 14; 16; 17; 23; 24  Most 
of these studies showed that among people with epilepsy there were significantly 
increased risks of death due to neoplasia, cerebrovascular disease, and respiratory 
disease.  Two studies also found an increased risk of death due to digestive diseases.17; 
24 Estimates pertaining to cardiovascular disease tended to show a smaller elevation of 
risk that were not statistically significant in the majority of the studies. 
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Discussion 
Limitations.  Our assessments of the quality of evidence of these studies are an attempt 
to set minimum standards for their likely validity.  The criteria we applied emphasize 
methods addressing sensitivity of case ascertainment, accuracy of diagnoses, and 
representativeness.  Inevitably, review processes such as ours involve qualitative 
judgments by reviewers, whose interpretations of study methods and applications of 
quality criteria are often not fully consistent: 50 percent of paired initial ratings were 
discordant, requiring reconsideration by the reviewers to achieve consensus.   
Our criteria for assessing quality of evidence did not address the problem of 
confounding, a source of bias in studies measuring risks associated with specific 
factors.  Confounding results from a mixing of effects of two or more causal risk factors 
that determine the measured outcome.  Among the studies we reviewed, there are 
many potential confounders.  For example, measurement of the risk of death by 
whether seizures are fully controlled or not (refractoriness) is potentially confounded by 
age, the types of seizures experienced (generalized tonic-clonic versus others), the 
underlying cause of epilepsy, and the presence of other comorbid conditions that may 
contribute to mortality.  Some studies we reviewed reduced the effect of confounders 
through methods involving stratification or multivariate analysis; others did not. 
The populations of these studies varied greatly.  Community population-based studies 
were more likely to be representative of the general population of people with epilepsy, 
but results from the specific populations of these studies may not be fully generalizable 
to other populations of developed countries, where factors such as the occurrence of 
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epilepsy, medical care for epilepsy, general health care availability, and preventive 
public health practices vary.  Studies of clinical cohorts that were not population-based 
vary much more in the extent to which their findings can be generalized.  Some 
represented a relatively broad distribution of epilepsy cases by cause and severity; 
others predominantly represented epilepsy cases with seizures resistant to treatment or 
accompanied by substantial comorbidities. 
Finally, our search strategy included general terms encompassing epilepsy-related 
mortality, but not terms for many specific causes, e.g., suicide.  Thus, it is possible that 
some studies focused solely on such specific causes—if not indexed more generally to 
mortality in databases we searched—may have been overlooked in our review.  
Interpretation.  Despite these limitations, several implications of this review are clear.  
Our findings, now obtained by means of a systematic, evidence-based review, confirm 
and strengthen the conclusions of previous reviews, indicating a significantly increased 
risk of premature mortality among the general population of people with epilepsy—more 
than two-fold, as measured across all age groups by standardized mortality ratios.   
Comparative risks of premature death from epilepsy by these measurements appear 
slightly higher in males than females and appear substantially greater in younger age 
groups. 
Mortality risk by age deserves further consideration.  High elevations of risk among 
people with epilepsy (SMR roughly seven-fold) are seen through the fourth or fifth 
decade of life; thereafter, the risks measured in relation to the general population 
appear to decline markedly as risks of competing causes of death rise for all people.  
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These standardized mortality ratios should, however, not be interpreted as indicating 
that the absolute risk of deaths associated with epilepsy (that is, deaths from epilepsy, 
its underlying conditions, or its consequences) decline among older adults. The actual 
rates of death from these causes cannot be deduced from SMRs. 
Several disease characteristics increase the risk of premature mortality among people 
with epilepsy.  Epilepsy causes categorized as structural/metabolic (‘symptomatic’) 
carry a higher risk than causes classified as genetic (‘idiopathic’) or unknown 
(‘cryptogenic’).  Within the structural/metabolic category, specific etiologic comorbidities 
indicating static or progressive encephalopathies acquired congenitally or in early 
childhood indicate an especially high risk, as do brain tumors.  People with epilepsy 
whose seizures do not fully remit under treatment and those with convulsions also carry 
a higher risk. 
SUDEP is an important cause of death.  The studies of SUDEP that we reviewed have 
serious limitations involving either case under-ascertainment or uncertainties in the 
prevalence of epilepsy in their populations, making it difficult to provide a summary 
estimate of its incidence.  Taking these limitations into account, it appears likely that the 
annual rate of SUDEP exceeds 1 case per 1000 people with epilepsy.  Among those 
whose seizures are not fully controlled, the rate appears several-fold higher.  In general, 
the rate appears lower in children. While beyond the scope of this review, more 
extensive explorations of SUDEP risk factors and incidence are found in other recent 
reviews.54-56 
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Finally, injuries—both unintentional and intentional—are important causes of premature 
death among people with epilepsy.  Further research is needed to better characterize 
these risks. Nevertheless, existing evidence indicates significantly elevated risks in 
particular for drowning, falls, and suicide. 
Implications.  Epilepsy-associated mortality imposes a significant burden on public 
health, and many of the specific causes of death associated with epilepsy—especially 
injuries, status epilepticus, and SUDEP—may be preventable.  Accordingly, health care 
providers, researchers, and public health professionals should give high priority and 
sufficient resources toward prevention efforts directed to these causes.  Health care 
systems should also ensure that all people with epilepsy have access as needed to high 
quality services, including access to specialty care, education, and social support 
services.  By serving to promote the best possible seizure control, as well as the 
reduction of medical and psychiatric comorbidities and their consequences, many 
premature deaths among people with epilepsy may be prevented.  
To this end, taking into account the limitations of evidence identified in this review, 
additional epidemiologic studies are needed as well as the development of methods and 
systems for long-term surveillance of mortality in people with epilepsy.  These can 
promote advances in prevention strategies, enable evaluations of applied prevention 
interventions, and elucidate population trends over time.  Such new studies and 
surveillance systems should be designed in conformity with current guidelines,57 with 
careful attention to: (a) the representativeness of study populations, (b) accuracy in 
identifying all epilepsy and unprovoked seizure diagnoses among decedents, and (c) 
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accuracy in identifying all deaths and their specific causes among people with epilepsy.  
These studies and systems should also identify specific epilepsy characteristics and 
comorbidities that potentially increase risk of death.  In sum, such epidemiologic studies 
and surveillance systems can enable future progress in reducing the public health 
burden of these premature deaths. 
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Tables and Figures 
 
Table 1.  Overall Mortality Risk among People with Epilepsy: All-age or Adult-only Populations 
Study Class Locality Pop'n Characteristic Cohort Size* 
Follow
-up 
(years) 
SMR 95% CI 
Population- or community-based studies, all ages or adults only  
Lhatoo 200115 1 England & Wales, UK Incident cohort, all ages 792 11.8† 2.1 1.8-2.4 
Lindsten 200016 1 Vasterbotten Co., Sweden Incident cases, adult cohort 107 10 2.5 1.2-3.2 
Hauser 198014 1 Rochester, MN, US Incident cases, all ages 618 13.3† 2.3 1.9-2.6 
Benn 200813 2 Northern Manhattan, US Incident epilepsy or unprovoked seizures, all ages 209 2.9
† 1.7 1.1-2.3 
Cockerell 19978 2 UK Incident cases, all ages 792 ≤9 3.0 2.5-3.7 
Morgan 200217 2 Cardiff & Glamorgan, UK Prevalent cases, all ages 3007 ≤4 2.1 1.7-2.6 
Olafsson 199818 2 Iceland Incident unprovoked seizures, all ages 224 ≤30 1.6 1.2-2.2 
Neligan 201110‡ 2 UK Incident cases, all ages 564 22.8 2.6 2.2-3.0 
Rakitin 201119 2 Estonia Incident cases, age ≥20 years 81 12.5† 2.6 1.8-3.5 
Population- or community-based studies, children only 
Sillanpaa 201022 1 Turku, Finland Incident & prevalent cases,  onset <16 y 245 40 6.4 5.9-7.0 
Nickels 201221 1 Rochester, MN, US Incident cases, <18 y 467 7.9† 6.9  
Camfield 200220 2 Nova Scotia, Canada Incident cases <17 y 692 13.9† 7.5 4.4-13.0 
Clinic-based studies, all ages or adults only 
Nilsson, 199724  3 Stockholm, Sweden Previously hospitalized for epilepsy 9061 ≤17 3.6 3.5-3.7 
Mohanraj 200623 3 Glasgow, UK Incident clinic referral cases 890 7† 1.4 1.2-1.7 
   Prevalent clinic referral cases 2689 7† 2.0 1.8-2.3 
Trinka 201312 3 Tyrol, Austria Cohort of attendees of epilepsy referral clinic 3334 
28.1≤2
9 2.2 2.0-2.4 
Granbichler 
201511§ 3 Tyrol, Austria 
Cohort of adult attendees of 
epilepsy referral clinic 4295 ≤39 1.7  (1.6-1.9) 
Clinic-based studies, children only 
Callenbach 200126 3 Netherlands Incident cases 472 5.0 7.0 2.4-11.5 
Berg 200425 3 Connecticut, US Incident cases <16 y representative sample 613 7.9 7.5 4.4-13.0 
* Number of persons with epilepsy followed 
† Median or mean follow-up period 
‡ Extended follow-up of cohort described in Cockerell 1997. 
§ Extended follow-up and expansion of cohort described in Trinka 2013. 
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Table 2.  Mortality by comorbid brain disorder 
Study Class Country Cases Follow-up  Measure 
Comorbid Condition 
Enceph MR/CP Brain Tumor CVD Dementia 
Lhatoo 
200115 1 United 
Kingdom 
Incident 11.8 SMR 25        
    HR  10.9 12.0 2.4  
Nickels 
201221 1 United States 
Incident, 
children 7.9 HR 12.8     
Camfield 
200220 
2 Canada Incident, 
children 
13.9 HR 22.0     
Cockerell 
19978 2 
United 
Kingdom Incident  ≤9.0 SMR 50     
Forsgren 
199630 
 
2 Sweden  
Prevalent,  
  Age 0-19 
  All  ages 
 
≤7.0 
6.6 
 
SMR 
SMR  
 
52.0 
5.8  
  
Hauser 
198014  United States Incident 13.3 SMR 11.0     
Neligan 
201110* 2 
United 
Kingdom Incident 22.8 SMR 18.6     
Keezer 
20169* 
2 United 
Kingdom 
Incident 23 HR   5.0 4.0 2.8 
Berg 
201332 
2 International Incident, 
children 
13.6 Rate 7.3 
  
 
 
Berg 
200425 3 United States 
Incident, 
children 7.9 SMR 33.5     
Callenbach 
200126 3 Netherlands 
Incident, 
children 5.0 SMR 22.9     
Loiseau 
200531 3 France Incident ≤1.0 SMR   41.5   5.4 
Granbichle
r 201511 
3 Austria Prevalent ≤39 SMR    2.6  
Notes 
Follow-up refers to median or mean duration of subject follow-up in years, reported or calculated from report 
data.  If not calculable, ‘≤’ signifies maximum duration of subject follow-up. 
Abbreviations: ‘Enceph’ – static or progressive encephalopathies, including major congenital or acquired central 
nervous system deficits, not specifically defined; ‘MR/CP’ – mental retardation (intellectual disability) or cerebral 
palsy; CVD – cerebrovascular disease. 
Hazard ratios (HRs) compare persons with epilepsy and comorbid condition with persons with epilepsy and not 
comorbid condition. 
Rate is number of deaths per year among 1000 children with epilepsy and comorbid condition. 
Lower limit of confidence interval exceeds 1.0 for all SMRs and HRs reported. 
*Follow-up reports of cohort described in Cockerell 1997. 
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Table 3.  Risk of death from injury among people with epilepsy 
Study Class Locality Cohort External Cause 
Risk 
Measure 
Risk Estimate  
(95% C.I.) 
All Injuries 
Fazel 201352 3 Sweden Population-based All aOR 3.6 (3.3–4.0) 
Nilsson 
199724 
3 Sweden Prior epilepsy 
   hospitalization All  SMR 5.6 (5.0-6.3) 
Rafnsson 
200127 
2 Iceland Population-based, 
incident unprovoked 
seizures 
All SMR 2.6 (1.6-6.5)a 
Granbichler 
201511 
3 Austria Hospital-based All SMR 2.0 (1.6-2.5) 
Unintentional Injuries 
Diekema  
   199353 2 United States 
Population-based,  
   children Drowning SMR 13.8  (7.0-27.0) 
Granbichler 
201511 
3 Austria Hospital-based Transport  
Submersion/ 
suffocation 
SMR 
SMR 
 
1.3 (0.6-2.5) 
2 (0.7-4.3) 
 
Fazel 201352 
 
3 
 
Sweden 
 
Population-based 
 
Drowning 
Vehicle 
Fall 
aOR 
aOR 
aOR 
7.7  (4.7–12.7) 
1.4  (1.1–1.8) 
8.5  (5.3–13.7) 
Mohanraj  
   200623 3 
United  
   Kingdom 
Epilepsy referral center, 
   incident cases All accidents SMR 4.8  (2.2–9.1) 
Nilsson 
199724 
3 Sweden Prior epilepsy 
   hospitalization 
Submersion/
suffocation 
Transport  
Falls 
Fire/flame 
SMR 
 
SMR 
SMR 
SMR 
8.2  (5.2-12.1) 
 
1.8  (0.9-3.4) 
4.6  (3.5-5.8) 
10.3  (5.8-17.0) 
Intentional Injuries 
Fazel 201352 
 
3 
 
Sweden 
 
Population-based 
 
Suicide 
Assault 
aOR 
aOR 
3.7 (3.3–4.2) 
2.8 (1·6–4.8) 
Granbichler 
201511 
3 Austria Hospital-based Suicide SMR 4.2 (2.0-8.1) 
Mohanraj  
   200623 3 
United  
   Kingdom 
Epilepsy referral center, 
   incident cases Suicide SMR 2.6 (0.5-7.5) 
Nilsson 
199724 
3 Sweden Prior epilepsy 
   hospitalization Suicide SMR 3.5 (2.6-4.6) 
Rafnsson 
200127 
2 Iceland Population-based, 
incident unprovoked 
seizures 
Suicide SMR 5.0 (1.3-12.8) a 
Notes: 
aOR refers to adjusted odds ratios for people with epilepsy compared to age- and sex-matched controls. 
a Recalculated to combine data for men and women. 
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Table 4.  Risk of death among people with epilepsy by category of disease causing death. 
Study Class Country Cohort Risk Measure 
Standardized Mortality RatiosRisk Estimate by Cause 
Neoplasia CVD Cerebrovasc Digestive Respiratory 
Hauser, 
198014 1 
United 
States Incident SMR 2.9 (2.1-3.9) 1.1 (0.8-1.5) 2.6 (1.8-3.6)  3.5 (1.6-6.6) 
Lindsten, 
200016 1 Sweden Incident SMR 3.4 (1.9-5.8) 1.8 (1.2-3.0) 4.2 (2.2-8.0)    
Keezer, 
20169 2 
United 
Kingdom Incident HR 4.2 (2.3–7.9)  4.0 (2.0-8.0)   
Morgan, 
200217 
2 United  
   Kingdom 
Prevalent SMR 1.5 (1.1-1.8) 1.2 (0.9-1.5) 2.7  (2.0-3.3) 2.4  (1.3-3.5) 1.7 (1.3-2.2) 
Nilsson, 
199724 3 Sweden Prevalent SMR 2.6(2.4-2.8) 3.1 (3.0-3.3)  5.1 (4.4-5.8) 4.0  (3.6-4.5) 
Mohanraj,  
   200623 3 
United  
   Kingdom Incident SMR 0.7 (0.4-1.2) 1.5  (0.9-2.3) 1.6 (0.8-2.9)   2.6  (1.5-4.0) 
Granbich-
ler, 
201511 
3 Austria Prevalent SMR 1.2 (1.0-1.4 1.6 (1.3-1.8) 2.6 (2.1-3.1) 0.8 (0.3-1.6) 1.9 (1.4-2.5) 
Notes 
Abbreviations: ‘CVD’ – cardiovascular disease, ‘Cerebrovasc’ – cerebrovascular disease. 
Parenthetic numbers denote 95% confidence intervals. 
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Search 
Screening 
Review for 
Inclusion 
Unduplicated citations from MEDLINE and Embase databases
Before November 2011: n=354
November 2011 - February 2014: n=141
March  2014 - June 2016: n=109
Additional citations from article bibliographies: n=3
Total titles and abstracts to be screened: 607
Titles and abstracts suggest eligibility under inclusion criteria 
(population, cohort or case-control studies in HIC, 
with full reports containing original data 
on epilepsy mortality occurrence)
Total to be reviewed in full: 219
Reviewed reports meeting inclusion criteria 
with relevant data of evidence Class 3 or better
Total included: 46
Figure 1.  Results of systematic search. 
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Figure 2.  Standardized Mortality Ratios by Age: Deaths from All Causes Among People with Epilepsy 
 
Source: Four class 1 and class 2 studies. 8; 14; 20; 22 
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Figure 3.  Standardized Mortality Ratios by Interval from Epilepsy Diagnosis* 
 
*Data points represent the midpoint of intervals from diagnosis described in individual studies.  Error 
bands indicate 95% confidence intervals. 
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Supporting Information 
 
Supporting Table 1a.  Search strategy and report screening criteria 
 
Ovid® MEDLINE 
Terms included any of the following Medical Subject Headings, with subheadings indicated by brackets 
and term combinations indicated by ‘AND’ used as a Boolean operator: 
1. Epilepsy [epidemiology] AND Epilepsy [mortality] 
2. Epilepsy AND Mortality 
3. Epilepsy AND ‘Sudden death’ [epidemiology] 
4. Epilepsy AND Death [etiology]  
5. Epilepsy AND ‘Wounds and Injuries’ (and subheadings) [mortality]  
6. 1 OR 2 OR 3 OR 4 OR 5 
Search limited to human studies. 
 
Embase®  
1. 'epilepsy'/mj AND ([article]/lim OR [review]/lim) AND [humans]/lim AND [embase]/lim AND [2014-
2016]/py  
2. 'mortality'/exp AND [2014-2016]/py   
3. 'epidemiology'/exp AND [embase]/lim AND [2014-2016]/py   
4. 1 and 2 and 3 
 
Criteria required to accept articles for full review: 
 Original reports providing new data including measures of mortality for people with epilepsy, e.g., 
mortality incidence rates, SMRs, proportionate mortality ratios, or other comparative risk ratios.   
 Population- or community-based, clinical cohort, or case-control studies included.   
 High-income country localities, as defined by World Bank. 
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Supporting Table 1b.  Criteria for Assessing Strength of Evidence 
Sensitivity of Epilepsy Case Ascertainment 
 1 = Screening methods appear likely to ascertain nearly all (≥ 85%) cases in population 
 2 = Screening methods appear likely to ascertain most (70 - 84%) cases in population 
 3 = Screening methods appear likely to ascertain majority (50 - 69%) of cases in population 
 4 = Screening methods appear unlikely to ascertain majority of cases in population OR 
information published is insufficient to assess 
 N/A = Not applicable: not a population-based study or sensitivity of methods of epilepsy case 
ascertainment not relevant to quality of study. 
Sensitivity of Mortality Case Ascertainment 
 1 = Fatalities appear likely to be recorded in nearly all (≥ 85%) cases in study population 
 2 = Fatalities appear likely to be recorded in most (70 - 84%) cases in study population 
 3 = Fatalities appear likely to be recorded in majority (50 - 69%) of cases in study population 
 4 = Fatalities appear unlikely to be recorded in majority of cases in study population OR 
information published is insufficient to assess 
Accuracy of Diagnoses of Epilepsy 
 1 = Cases are diagnosed (or confirmed) by specialist  clinician (i.e., with neurologic training), 
AND ILAE case definition applied 
 2 = Cases are often diagnosed by non-specialist clinician, OR minor deviation from ILAE case 
definition 
 3 = All or substantial proportion of cases diagnosed based on self-report or non-clinical 
sources with specified criteria judged to have fair positive predictive value 
 4 = All or substantial proportion of cases diagnosed with poorly defined criteria from non-
clinical sources; positive predictive value judged to be poor OR information published is 
insufficient to assess 
Accuracy of Diagnoses of Cause of Death 
 1 = Determined mainly from either autopsy, ME medical examiner/coroner investigation, or 
other clinical investigation (e.g., review of medical records, structured interview of survivors or 
“verbal autopsy”) 
 2 = Determined largely or wholly from death certificate data, when such data are judged to 
have good positive predictive value for the specific causes of interest 
 3 = Determined largely or wholly from death certificate data, when such data are judged to 
have only fair positive predictive value for the specific causes of interest 
 4 = Other sources of data deemed to have poor positive predictive value for the causes of 
interest OR information published is insufficient to assess 
Representativeness of the study population 
 1 = Cohort studies of incident epilepsy whose enrolled cases appear highly representative of 
the population of interest 
 2 = Studies of prevalent epilepsy whose enrolled cases appear highly representative of the 
population of interest 
 3 = Studies of epilepsy whose enrolled cases appear somewhat representative of the 
population of interest 
 4 = Studies of epilepsy whose enrolled cases appear poorly representative of the population of 
interest or where representativeness cannot be assessed. 
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Supporting Table 2.  All-cause mortality among people with epilepsy by sex 
Study Class Country Pop'n Characteristic 
SMR (95% CI) 
Females Males 
Benn 200813 2 United States Incident epilepsy or unprovoked seizure 1.7 (1.0-2.5) 1.6 (0.8-2.8) 
Hauser 198014 1 United States Incident epilepsy, idiopathic cause 1.6   2.1   
Lindsten 200016 1 Sweden Incident cases, aged >16 years 2.3 (1.4-3.7) 2.7 (1.8-3.9) 
Morgan 200217 2 United Kingdom Prevalent cases 2.0 (1.5-2.6) 2.3 (1.7-2.9) 
Nilsson, 199724 3 Sweden Previous epilepsy hospitalization 3.4 (3.3-3.6) 3.7 (3.6-3.9) 
Rafnsson, 200127 2 Iceland Incident epilepsy or unprovoked seizure 0.8 (0.4-1.5) 2.3 (1.6-3.1) 
Trinka 201312 3 Austria Referrals to specialized clinic  1.9 (1.7-2.2) 2.4 (2.1-2.6) 
 
Supporting Table 3.  All-cause mortality among people with epilepsy by age  
Author Class Country Age in Years SMR CI 
Risk Described by Age of Epilepsy Onset 
Berg 200425 3 United States <16 7.5 4.38-13.0 
Callenbach 200126 3 Netherlands <16 7.0 2.4-11.5 
Camfield 200220 2 Canada <17 6.9  
Lindsten 200016 1 Sweden 15-39 9.5 3.1-29.4 
   40-59 10.7 6.5-17.6 
   60-79 2.4 1.6-3.8 
   >80 1.3 0.7-2.4 
Moseley 201328 1 United States <0.08* 46.4 12.7-119.3 
   <1  22.3 9.6-43.8 
   1- 17  5.67 2. 5-11.2 
Risk Described by Age at Follow-up 
Cockerell 19978 2 United Kingdom 0-49 7.6 4.2-12.5 
   50-59 8.6 4.7-14.1 
   60-69 3.6 2.2-5.5 
   70-79 1.9 1.2-2.8 
   >80 2.6 1.8-3.6 
Hauser 198014 1 United States 0-24 8.5 5.4-12.9 
   25-44 7.7 5.1-11.0 
   45-54 3.5 2.0-5.7 
   55-64 3.0 2.0-4.5 
   65-74 1.5 1.0-2.2 
   >74 1.4 1.1-1.9 
Nilsson 199724 3 Sweden 15-34 14.4 12.4-16.7 
   35-54 10.1 9.4-10.9 
   55-74 4.0 3.9-4.2 
   >74 2.1 2.0-2.3 
Sillanpaa 201022 1 Finland <16 6.4 5.9-7.0 
*Age of epilepsy onset <1 month. 
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Supporting Table 4.  Standardized mortality ratios by seizure type 
Study Class Country Cases Generalized GTC Partial 
Lindsten 2000 1 Sweden Incident cases (males) 
 
3.9 2.1 
Benn 2008 2 United States 
Incident epilepsy and first  
unprovoked seizure 
1.3  1.8 
Rakitin 2011 2 Estonia Incident cases (adults)  2.7* 1.5† 
*Partial seizures with secondary generalization 
†Simple partial seizures 
 
Supporting Table 5. Standardized mortality ratios by epilepsy etiology 
Study Class Country Cryptogenic Idiopathic Crypt/Idio Symptomatic 
Hauser 198014 1 US   1.8 (1.4-2.3) 2.2 (1.8-2.7) 
Lhatoo 200115 1 UK  1.3 (0.9-1.9)  3.7 (2.9-4.6) 
Benn 200813 2 US   0.9 (0.2–2.2) 2.3 (1.5–3.4) 
Cockerell 19978 2 UK  1.6 (1.0-2.4)  4.3 (3.3-5.5) 
Neligan 201110 2 UK   1.7 (1.3-2.1) 3.7 (3.1-4.4) 
Olafsson 199818 2 Iceland 1.3 (0.8-1.9)   2.3 (1.4-3.5)‡ 
      4.1 (2.4-6.6)§ 
Rakitin 201119 2 Estonia 2.1 (1.1–3.6)   3.6 (2.3–5.2) 
Mohanraj 200623 3 UK 1.1 (0.7–1.6) 3.1 (0.9–7.8)  1.4 (1.1-1.8) 
Trinka 201312 3 Austria 1.7 (1.5-1.9) 2.1 (1.4-3.0)  2.8 (2.6-3.2) 
Category abbreviations: Crypt/Idio – cryptogenic and idiopathic categories combined or not 
distinguished;. 
‡15-year follow-up 
§≤30-year follow-up 
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Supporting Table 6.  Mortality among study subjects with seizures refractory to treatment 
Study Class Country Cohort Rate/  1000 SMR RR OR 
Sillanpaa 199834 1 Finland Not seizure-free, onset age <16 years   
9.3  
(3.8-22.7)* 
 
Annegers 200033 2 International Receiving vagal nerve  stimulation 
7.9  
(5.2-11.8) 
3.6  
(2.3-5.4)  
 
Ridsdale 201138 2 UK Not seizure-free    1.3  (1.2-1.4)* 
Sperling 200535 2 United States Post epilepsy surgery  with recurrent seizures. 
11.4  
(7.0-18.3)  
13.4  
(1.8-100.6)* 
 
Vickrey 199736 2 United States Evaluated for epilepsy surgery   
4.3  
(1.8-10.2)
†
 
 
Lip 199237 3 UK Referred to tertiary 
epilepsy center 
7.3  
(4.5-11.8) 
     
Trinka 201312 3 Austria Not seizure-free  2.4  (2.2-2.6)  
 
Notes: 
Annual rates per 1000 persons with epilepsy.  Numbers in parentheses refer to 95% confidence intervals. 
*Comparison of people who are not seizure-free with those who are seizure-free. 
†Comparison of experience following evaluation among people who are not surgically treated and those who are 
surgically treated. 
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Supporting Table 7.  Risk of SUDEP 
Study Class Country Cohort Rate (95% C.I.) 
Community-based studies 
   Ficker 199841 2 Rochester, MN, US Prevalent 0.35 (0.17-0.68) 
   Ackers 201139 3 UK Prevalent 0.33 (0.15-0.64) 
   Donner 200140 3 Canada Prevalent, <18 years of age 0.20 (0.13-0.29) 
   Holst 201342 3 Denmark Prevalent, ≤35 years of age 0.41 (0.31-0.55) 
   Opeskin 200343 3 Victoria, Australia Prevalent 
a
 1.28 (0.96-1.70) 
   Mohanraj 200623 3 Glasgow, UK Incident 1.08 (0.47-2.33) 
   Tennis 199544 3 Saskatchewan, Canada Prevalent 
a
 
0.54 (0.33-0.87) 
1.35b (1.00-1.83) 
   Weber 200545 3 Basel, Switzerland Prevalent, children 0.43 (0.14-1.18) 
Clinic-based studies 
   Nilsson 200348 1 Sweden Refractory epilepsy,  
not eligible for surgery 
6.3 (1.7-16.1) 
   Annegers 200033 2 International Vagus nerve stimulation cohort 4.1 (2.3-7.2) 
   Derby 199646 2 UK Refractory epilepsy 1.5 (0.8-2.7) 
   Timmings 199849 2 Cardiff, UK Referrals to outpatient clinic 2.0 (1.1-3.4) 
   Lip 199237 3 Glasgow, UK Refractory epilepsy 4.9 (2.6-8.8) 
   Mohanraj 200623 3 Glasgow, UK Referrals to outpatient clinic 2.4 (1.8-3.2) 
   Nashef 199550 3 UK School for learning disability 3.4 (1.9-5.8) 
   Nashef 199547 3 UK Referrals to outpatient clinic 5.9 (3.1-11.0) 
   Walczak 200151 3 Minneapolis, MN, US Referral to outpatient clinic 1.2 (0.8-1.9) 
Annual rate per 1000 persons with epilepsy 
aBased on estimated population of people with epilepsy 
bEstimate adjusted for sensitivity 
 
 
Supporting Table 8.  Risk of Death from Status Epilepticus among People with Epilepsy 
Study Class Locality Cases Rate/1000  
Lhatoo 2001 1 United Kingdom Population-based, all ages 0.09 0.005-0.57 
Ackers 2011 3 United Kingdom Population-based, children 0.22 0.09-0.51 
Lip 1992 3 United Kingdom Refractory epilepsy 0.41 0.02-2.63 
Nashef 1995 3 United Kingdom School for learning disability 0.97 0.03-2.66 
 
 
 
